Allspring Global Investments Holdings LLC Sells 29,796 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Allspring Global Investments Holdings LLC lessened its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 61.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,941 shares of the company’s stock after selling 29,796 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Kiniksa Pharmaceuticals International were worth $524,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. purchased a new stake in Kiniksa Pharmaceuticals International in the second quarter worth $233,000. Toth Financial Advisory Corp purchased a new stake in Kiniksa Pharmaceuticals International in the second quarter worth $296,000. Wealth Enhancement Advisory Services LLC grew its stake in Kiniksa Pharmaceuticals International by 13.6% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company’s stock worth $430,000 after purchasing an additional 1,846 shares during the period. Pallas Capital Advisors LLC purchased a new stake in Kiniksa Pharmaceuticals International in the second quarter worth $236,000. Finally, Voya Investment Management LLC grew its stake in Kiniksa Pharmaceuticals International by 54.4% in the first quarter. Voya Investment Management LLC now owns 30,866 shares of the company’s stock worth $686,000 after purchasing an additional 10,878 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on KNSA. Citigroup upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a research report on Monday, October 13th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $46.86.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $37.67, for a total value of $465,902.56. Following the completion of the sale, the chief operating officer owned 28,684 shares of the company’s stock, valued at approximately $1,080,526.28. This trade represents a 30.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ross Moat sold 3,523 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $35.31, for a total value of $124,397.13. Following the completion of the sale, the insider directly owned 9,415 shares of the company’s stock, valued at approximately $332,443.65. The trade was a 27.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 905,298 shares of company stock worth $32,343,574 in the last 90 days. 53.48% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International Trading Up 0.4%

Kiniksa Pharmaceuticals International stock opened at $38.93 on Friday. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of 973.49 and a beta of 0.16. The stock has a fifty day simple moving average of $36.42 and a two-hundred day simple moving average of $30.34. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $39.79.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.